03 — Portfolio

Twenty-three syndicate investments.

Selected and led from preclinical through proof of concept. Status reflects current public stage or last reported milestone.

Portfolio

Twenty-three syndicate investments across oncology, immunology, and platform.

Selected and led from preclinical through proof of concept. Status reflects current public stage or last reported milestone.

Open the portfolio

P/001

Cullinan Oncology

Onc · NASDAQ: CGEM

P/002

Arcus Biosciences

Onc · NYSE: RCUS

P/003

Orna Therapeutics

Plat · Series B · 2023

P/004

Harpoon Therapeutics

Onc · Acquired by Merck · 2024

P/005

ORIC Pharmaceuticals

Onc · NASDAQ: ORIC

P/006

NextCure

Onc · NASDAQ: NXTC

P/007

Werewolf Therapeutics

Imm · NASDAQ: HOWL

P/008

Magnet Biomedicine

Onc · Series A · 2023

P/009

Halda Therapeutics

Onc · Series A · 2024

P/010

Anavo Therapeutics

Plat · Series A · 2024

P/011

Breakpoint Therapeutics

Onc · Series A · 2023

P/012

Delphia Therapeutics

Onc · Series A · 2024

P/013

Dren Bio

Plat · Series B · 2023

P/014

EpiBiologics

Onc · Series A · 2024

P/015

Incendia Therapeutics

Onc · Series A · 2024

P/016

LiberoThera

Imm · Series B · 2023

P/017

Light Horse

Plat · Series A · 2024

P/018

Normunity

Imm · Series A · 2023

P/019

Storm Therapeutics

Onc · Series B · 2023

P/020

Theo Pharmaceuticals

Plat · Series A · 2024

P/021

Transition Bio

Plat · Series C · 2023

P/022

Vertero

Onc · Series A · 2024

P/023

Cellvie

Plat · Series A · 2023